Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Evonik investing $28m on initial expansion in Germany

By Chris Newmarker | May 5, 2020

Evonik Hanau Germany API plant

Workers at Evonik’s active pharmaceutical ingredients plant in Hanau, one of two in Germany that are slated for expansion. [Image courtesy of Evonik]

Evonik recently announced that it will spend an initial €25 million (equivalent to nearly $28 million) to expand its Dossenheim and Hanau facilities in Germany.

The expansion is meant to meet the growing demand for the contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates within Europe. Evonik expects to complete the €25 million first phase by mid-2021, with the entire project finalized before 2024.

“The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets,” said Thomas Riermeier, SVP of Evonik’s Health Care business line. “The expansion of our Dossenheim and Hanau sites in Germany is now underway to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.”

Dr. Andreas Meudt, VP of Exclusive Synthesis for the Health Care business line of Evonik, added that expansion of the two multi-purpose cGMP sites in Germany will widen Evonik’s ability to support highly complex customer projects.

Complex API projects —  often associated with oncological, anti-viral and other specialized drug products — typically require a range of advanced technologies including continuous processing, highly pure PEGs and mPEGs, catalysis and cryogenic chemistry, according to Evonik.

Tell Us What You Think! Cancel reply

Related Articles Read More >

analyzing medical sample
Expert answers to nitrosamine impurity questions
Touchlight
Touchlight inks patent license deal with Pfizer related to the use of dbDNA in mRNA products
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards